Frontiers in Cancer Science 2025: Attend the Singapore International Cancer Conference

October 23, 2025 by

By Soo Chin Lee, MBBS, MMed, MRCP, and Reshma Taneja, PhD, cochairs of the Frontiers in Cancer Science 2025 conference

Singapore will once again welcome the global cancer research community for the 17th Frontiers in Cancer Science (FCS) conference, taking place November 5-7, 2025, at the NUS University Cultural Centre. Since its beginnings in 2009, FCS has grown into Asia’s leading cancer research meeting, bringing together scientists, clinicians, students, and industry partners to exchange knowledge and spark collaborations across disciplines.

AACR-FCS 2025 Education Sessions

In partnership with the American Association for Cancer Research (AACR), FCS 2025 will feature the popular Education Sessions, designed to highlight cutting-edge areas of cancer research and nurture scientific exchange between established experts and the next generation of researchers.

Confirmed speakers include Paul Boutros, PhD, MBA, (University of California, Los Angeles); Daniel Durocher, PhD, (Lunenfeld-Tanenbaum Research Institute, Canada); and Joanne Ngeow, MBBS, MRCP, MPH, (Lee Kong Chian School of Medicine, Nanyang Technological University, Singapore).

These sessions will set the stage for in-depth discussions on genomics, data science, and translational oncology.

Scientific Highlights

Across three days, FCS 2025 will feature plenary lectures, thematic sessions, poster presentations, and lightning talks spanning:

  • cancer genomics and precision medicine;
  • immuno-oncology and novel therapeutics;
  • cancer data science and artificial intelligence;
  • tumor microenvironment and metabolism; and
  • translational and clinical advances in hematologic and solid malignancies.

The conference provides early-career researchers with opportunities to present their findings in poster sessions and lightning talk presentations, engage with leaders in the field, and compete for awards recognizing outstanding research. The best posters will be recognized with prizes, including two travel grants of $2,500 USD each to support attendance at the AACR Annual Meeting 2026.

Speakers From Singapore and Beyond

FCS 2025 will bring together a diverse faculty of distinguished researchers and clinicians from Singapore and across the globe. Participants can look forward to hearing insights from international leaders alongside regional experts, reflecting the conference’s commitment to fostering collaboration and showcasing excellence in cancer research from Asia and beyond.

FCS is jointly organized by the Cancer Science Institute of Singapore; Duke-NUS Medical School; Genome Institute of Singapore; Institute of Molecular and Cell Biology; Lee Kong Chian School of Medicine/Nanyang Technological University; National Cancer Centre Singapore; National University Cancer Institute, Singapore; and Yong Loo Lin School of Medicine, National University of Singapore.

View the program highlights for this year’s exciting international conference from Singapore, as well as information about registration.

We warmly welcome you to Frontiers in Cancer Science 2025 and hope to see you in Singapore!

Soo Chin Lee, MBBS, MMed, MRCP, obtained her medical degrees from the National University of Singapore and the Royal College of Physicians, United Kingdom, and completed a fellowship in cancer genetics at Johns Hopkins School of Medicine. She was head of the Department of Haematology-Oncology at the National University Cancer Institute, Singapore (NCIS). She is currently senior consultant and associate director of research at NCIS and professor and senior principal investigator at the Cancer Science Institute of Singapore, National University of Singapore. She is ex-chairperson of the Chapter of Medical Oncologists, Academy of Medicine, Singapore, and was a member of the Singapore Ministry of Health Specialist Accreditation Board for Medical Oncology. She specializes in breast cancer and directs the Cancer Genetics Program at NCIS. Lee was awarded the National Medical Research Council Singapore (NMRC) Senior Clinician Scientist Award three times and is Distinguished Senior Clinician awardee by the Singapore Ministry of Health. Her research interests are in developing novel therapeutics and predictive biomarkers in breast cancer and pharmacogenetics. She sits on drug advisory boards for breast cancer drugs for multiple international pharmaceutical companies and directs the Haematology-Oncology Research Group (HORG), a cancer clinical trials unit that supports ~200 phase I-III therapeutics clinical trials in cancer at NCIS.

Reshma Taneja, PhD, obtained her doctoral degree in molecular biology from the Indian Institute of Science, in Bangalore, India. Her postdoctoral training in the laboratory of Pierre Chambon in Strasbourg, France was on retinoic acid receptor signaling. She started her laboratory at the Mount Sinai School of Medicine in New York City and focused on cellular differentiation mechanisms using skeletal muscle as a model system. In 2008, she relocated to the National University of Singapore where she is currently head of the Department of Physiology. Her research program currently focuses on understanding molecular mechanisms that drive oncogenesis and metastasis in a paediatric cancer, rhabdomyosarcoma.